'''Ibipinabant''' ('''SLV319''', '''BMS-646,256''') is a drug used in scientific research which acts as a potent and highly selective [[cannabinoid receptor 1|CB<sub>1</sub>]] [[Antagonist (pharmacology)|antagonist]].<ref>{{cite journal | last1 = Lange | first1 = JH | last2 = Coolen | first2 = HK | last3 = Van Stuivenberg | first3 = HH | last4 = Dijksman | first4 = JA | last5 = Herremans | first5 = AH | last6 = Ronken | first6 = E | last7 = Keizer | first7 = HG | last8 = Tipker | first8 = K | last9 = McCreary | first9 = AC | last10 = Veerman | first10 = Willem | last11 = Wals | first11 = Henri C. | last12 = Stork | first12 = Bob | last13 = Verveer | first13 = Peter C. | last14 = Den Hartog | first14 = Arnold P. | last15 = De Jong | first15 = Natasja M. J. | last16 = Adolfs | first16 = Tiny J. P. | last17 = Hoogendoorn | first17 = Jan | last18 = Kruse | first18 = Chris G. | title = Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists | journal = Journal of Medicinal Chemistry | volume = 47 | issue = 3 | pages = 627–43 | year = 2004 | pmid = 14736243 | doi = 10.1021/jm031019q | display-authors = 8 }}</ref> It has potent [[anorectic]] effects in animals,<ref>{{cite journal | last1 = Need | first1 = AB | last2 = Davis | first2 = RJ | last3 = Alexander-Chacko | first3 = JT | last4 = Eastwood | first4 = B | last5 = Chernet | first5 = E | last6 = Phebus | first6 = LA | last7 = Sindelar | first7 = DK | last8 = Nomikos | first8 = GG | title = The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats | journal = Psychopharmacology | volume = 184 | issue = 1 | pages = 26–35 | year = 2006 | pmid = 16328376 | doi = 10.1007/s00213-005-0234-x }}</ref> and was researched for the treatment of [[obesity]], although CB<sub>1</sub> antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with [[rimonabant]], and so ibipinabant is now only used for laboratory research, especially [[structure-activity relationship]] studies into novel CB<sub>1</sub> antagonists.<ref>{{cite journal | last1 = Lange | first1 = JH | last2 = Van Stuivenberg | first2 = HH | last3 = Veerman | first3 = W | last4 = Wals | first4 = HC | last5 = Stork | first5 = B | last6 = Coolen | first6 = HK | last7 = McCreary | first7 = AC | last8 = Adolfs | first8 = TJ | last9 = Kruse | first9 = CG | title = Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 15 | issue = 21 | pages = 4794–8 | year = 2005 | pmid = 16140010 | doi = 10.1016/j.bmcl.2005.07.054  }}</ref><ref>{{cite journal | last1 = Srivastava | first1 = BK | last2 = Joharapurkar | first2 = A | last3 = Raval | first3 = S | last4 = Patel | first4 = JZ | last5 = Soni | first5 = R | last6 = Raval | first6 = P | last7 = Gite | first7 = A | last8 = Goswami | first8 = A | last9 = Sadhwani | first9 = N | last10 = Patel | first10 = Harilal | last11 = Mishra | first11 = Bhupendra | last12 = Solanki | first12 = Manish | last13 = Pandey | first13 = Bipin | last14 = Jain | first14 = Mukul R. | last15 = Patel | first15 = Pankaj R. | last16 = Patel | first16 = P. R. | title = Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model | journal = Journal of Medicinal Chemistry | volume = 50 | issue = 24 | pages = 5951–66 | year = 2007 | pmid = 17979261 | doi = 10.1021/jm061490u | display-authors = 8 }}</ref><ref>{{cite journal | last1 = Srivastava | first1 = BK | last2 = Soni | first2 = R | last3 = Joharapurkar | first3 = A | last4 = Sairam | first4 = KV | last5 = Patel | first5 = JZ | last6 = Goswami | first6 = A | last7 = Shedage | first7 = SA | last8 = Kar | first8 = SS | last9 = Salunke | first9 = RP | last10 = Gugale | first10 = Shivaji B. | last11 = Dhawas | first11 = Amol | last12 = Kadam | first12 = Pravin | last13 = Mishra | first13 = Bhupendra | last14 = Sadhwani | first14 = Nisha | last15 = Unadkat | first15 = Vishal B. | last16 = Mitra | first16 = Prasenjit | last17 = Jain | first17 = Mukul R. | last18 = Patel | first18 = Pankaj R. | title = Bioisosteric replacement of dihydropyrazole of 4S-(−)-3-(4-chlorophenyl)-N-methyl-N'-(4-chlorophenyl)-sulfonyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole | journal = Bioorganic & Medicinal Chemistry Letters | volume = 18 | issue = 3 | pages = 963–8 | year = 2008 | pmid = 18207393 | doi = 10.1016/j.bmcl.2007.12.036 | display-authors = 8 }}</ref>
